Nesfatin-1 in cardiovascular orchestration: From bench to bedside. (June 2020)

• Record Type: Journal Article
• Authors: Angelone, Tommaso; Rocca, Carmine; Pasqua, Teresa
• Is Part Of: Pharmacological research. Volume 156(2020)
• Publication Date: 2020-06
• Subjects: ACTH adrenocorticotropin -- AgRP agouti-related peptides -- AMI acute myocardial infarction -- AQP aquaporin -- ARC arcuate nucleus -- ARTS-1 aminopeptidase regulator of TNRF1 shedding -- BMI body mass index -- CAD coronary artery disease -- cAMP cyclic adenosine monophosphate -- CART amphetamine-regulated transcript -- CCK cholecystokinin -- cGMP cyclic guanosine monophosphate -- CNS central nervous system -- CVD cardiovascular diseases -- DRG dorsal root ganglia -- ENaC epithelial sodium channel -- ERK1/2 extracellular signal-regulated kinases1/2 -- HbA1c hemoglobin A1c -- HOMA-IR homeostatic model assessment for insulin resistance -- HPA hypothalamic-pituitary-adrenal -- HUVEC human vascular endothelial cells -- ICV intracerebroventricular -- MCH melanin-concentrating hormone -- MDD major depressive disorder -- MetS metabolic syndrome -- MMP matrix metalloproteinase -- NEFA DNA binding/EF-hand/acidic protein -- NO nitric oxide -- NPR-A natriuretic peptide receptor A -- NPY/AGRP neuropeptide Y/agouti related peptide -- NPY neuropeptide Y -- NST nucleus of the solitary tract -- NSTEMI non-ST segment elevation myocardial infarction -- NUCB2 nucleobindin 2 -- OT oxytocin -- PCOS polycystic ovary syndrome -- PDE phosphodiesterase -- PKA protein kinase A -- PKC protein kinase C -- PKG protein kinase G -- POMC pro-opiomelanocortin -- PPARγ peroxisome proliferator-activated receptor γ -- PTX pertussis toxin -- PVN paraventricular nucleus -- RISK reperfusion injury salvage kinase -- SAFE survivor activating factor enhancement -- SERCA sarco-endoplasmic reticular Ca-ATPase -- SON supraoptic nucleus -- TNFR1 tumor necrosis factor receptor 1 -- VSMCs vascular smooth muscle cells -- α-MSH α-melanocyte stimulating hormone; Nucleobindin 2 -- Nesfatin-1 -- Feeding behavior -- Cardiovascular diseases -- Biomarker; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Research -- Periodicals; Médicaments -- Recherche -- Périodiques; Pharmacologie -- Périodiques; 615.105
• DOI: 10.1016/j.phrs.2020.104766
• Languages: English
• ISSNs: 1043-6618

Abstract

Graphical abstract: Abstract: Since the discovery of Nesfatin-1 in 2006, intensive research was finalized to further and deeper investigate the precise physiological functions of the peptide at both central and peripheral levels, rapidly enriching the knowledge regarding this intriguing molecule. Nesfatin-1 is a hypothalamic peptide generated via the post-translational processing of its precursor Nucleobindin 2, a protein supposed to play a role in many biological processes thanks to its ability to bind calcium and to interact with different intracellular proteins. Nesfatin-1 is mainly known for its anorexic properties, but it also controls water intake and glucose homeostasis. Recent experimental evidences describe the peptide as a possible direct/indirect orchestrator of central and peripheral cardiovascular control. A specific Nesfatin-1 receptor still remains to be identified although numerous studies suggest that the peptide activates extra- and intracellular regulatory pathways by involving several putative binding sites. The present paper was designed to systematically review the latest findings about Nesfatin-1, focusing on its cardiovascular regulatory properties under normal and physiopathological conditions. The hope is to provide the conceptual basis to consider Nesfatin-1 not only as a pleiotropic neuroendocrine molecule, but also as a homeostatic modulator of the cardiovascular function and with a crucial role in cardiovascular diseases.